Immune Thrombocytopenia (ITP)
Acquired Autoimmune Anti-Platelet Destruction Disorder
Primary risk age: 2 to 6 Years (Often follows a viral infection)
- Urgency
- Moderate
- Typical age
- 2 to 6 Years (Often follows a viral infection)
- Body system
- Hematological System
Typical course: Spontaneous resolution typically occurs within 2 to 8 weeks; chronic ITP persists beyond 12 months in a minority of cases.
Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13
1. Summary & Pathophysiology
Acquired Autoimmune Anti-Platelet Destruction Disorder
Pathophysiology (Development Path)
Autoantibodies (IgG) bind to glycoproteins on the surface of the child's platelets. These antibody-coated platelets are recognized as foreign and rapidly cleared by macrophages in the spleen, leading to a sudden drop in the peripheral platelet count.
Primary Causes & Etiology
An autoimmune reaction triggered by a recent viral infection (e.g., Varicella, EBV, or Upper Respiratory Infection) that prompts the generation of cross-reactive antibodies.
2. Symptom Continuum
- Early Onset Signs
Sudden appearance of petechiae (pinpoint red-purple spots) and purpura (bruising) in a healthy child, often without any history of trauma.
- Progressive Phase
Multiple bruises across the extremities and trunk, bleeding from the gums, and recurrent epistaxis (nosebleeds) that are difficult to stop.
- Severe Indicators
Internal bleeding, marked by hematuria (blood in urine), melena or hematochezia (blood in stool), and intracranial hemorrhage (rare, occurring in <1% of cases, marked by severe headache, vomiting, or altered consciousness).
3. Clinical Verification
Complete blood count showing isolated thrombocytopenia (platelet count <100,000/µL, often <20,000/µL) with normal white and red blood cell counts. Bone marrow biopsy is performed if atypical features are present.
4. Care & Elements Plan
Primary Care Treatment Plan
Most cases are acute and self-limiting; a "watch and wait" approach is appropriate if bleeding is minimal. For active bleeding or extremely low platelets, administer intravenous immunoglobulin (IVIG) or systemic corticosteroids.
Home Support Elements
Avoid contact sports and rough play to prevent trauma. Do not administer aspirin, ibuprofen, or other anti-platelet medications. Monitor for any signs of head injury.
Generic Active Ingredients (No Brands)
- Intravenous Immunoglobulin (IVIG - generic active ingredient to block splenic clearing of platelets)
- Methylprednisolone or Prednisone (generic systemic steroid active ingredients to suppress antibody production).
Lists active elements only. Never administer self-designed therapies.
5. Doctor Critical Lines
Critical Thresholds: When to See a Doctor
Seek immediate emergency evaluation if the child developments a severe headache, persistent vomiting, blood in the urine or stool, or an uncontrollable nosebleed.
6. Vaccine & Prevention
Routine Prophylaxis (Prevention)
No preventative measures exist, as the condition represents a transient post-viral autoimmune response.
Immunization Context
Routine childhood immunizations should be maintained; avoid live vaccines during high-dose steroid therapy.
7. Timelines & Outlook
Active Timeline
Spontaneous resolution typically occurs within 2 to 8 weeks; chronic ITP persists beyond 12 months in a minority of cases.
Expected Prognosis
Excellent. Up to 80% of children recover spontaneously within 6 months without long-term complications or a recurrence.
Potential Untreated Complications
Severe bleeding (menorrhagia in adolescent girls, gastrointestinal hemorrhage), and intracranial hemorrhage.
